Literature DB >> 32348510

Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management.

Giorgio Trivioli1, Benjamin Terrier2, Augusto Vaglio1.   

Abstract

Eosinophilic granulomatosis with polyangiitis is characterized by asthma, blood and tissue eosinophilia and small-vessel vasculitis. The clinical presentation is variable, but two main clinic-pathologic subsets can be distinguished: one hallmarked by positive ANCA and predominant 'vasculitic' manifestations (e.g. glomerulonephritis, purpura and mononeuritis multiplex) and the other by negative ANCA and prominent 'eosinophilic' manifestations (e.g. lung infiltrates and cardiomyopathy). The pathogenesis is not fully understood but probably results from the interplay between T and B cells and eosinophils. Eosinophilic granulomatosis with polyangiitis must be differentiated from several conditions, including hypereosinophilic syndromes and other small-vessel vasculitides. The overall survival is good; however, patients frequently relapse and have persistent symptoms. The recently developed monoclonal antibodies targeting B cells and eosinophilopoietic cytokines such as IL-5 are emerging as valid alternatives to conventional immunosuppressive therapies. In this review, we discuss the essential features of eosinophilic granulomatosis with polyangiitis, with particular respect to the most relevant issues concerning clinical presentation and management.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ANCA; asthma; hypereosinophilia; mepolizumab; rituximab; vasculitis

Year:  2020        PMID: 32348510     DOI: 10.1093/rheumatology/kez570

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

Review 1.  Regulatory T Cells in Autoimmune Vasculitis.

Authors:  Ke Jin; Simon Parreau; Kenneth J Warrington; Matthew J Koster; Gerald J Berry; Jörg J Goronzy; Cornelia M Weyand
Journal:  Front Immunol       Date:  2022-02-28       Impact factor: 7.561

2.  Gut Microbiota and Associated Mucosal Immune Response in Eosinophilic Granulomatosis with Polyangiitis (EGPA).

Authors:  Elena Niccolai; Alessandra Bettiol; Simone Baldi; Elena Silvestri; Leandro Di Gloria; Federica Bello; Giulia Nannini; Federica Ricci; Maria Nicastro; Matteo Ramazzotti; Augusto Vaglio; Gianluca Bartolucci; Giacomo Emmi; Amedeo Amedei; Domenico Prisco
Journal:  Biomedicines       Date:  2022-05-24

3.  Pneumonia and seizures due to hypereosinophilic syndrome-organ damage and eosinophilia without synchronisation: A case report.

Authors:  Tetsuro Ishida; Tomonori Murayama; Seiju Kobayashi
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

4.  Clinical Significance of MPO-ANCA in Eosinophilic Granulomatosis With Polyangiitis: Experience From a Longitudinal Chinese Cohort.

Authors:  Suying Liu; Linna Han; Yanhui Liu; Jun Yang; Yu Zhang; Mengtao Li; Xinping Tian; Xiaofeng Zeng; Li Wang; Fengchun Zhang
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

Review 5.  Imaging of intestinal vasculitis focusing on MR and CT enterography: a two-way street between radiologic findings and clinical data.

Authors:  Mehrnam Amouei; Sara Momtazmanesh; Hoda Kavosi; Amir H Davarpanah; Ali Shirkhoda; Amir Reza Radmard
Journal:  Insights Imaging       Date:  2022-09-04

Review 6.  Neutrophils in ANCA-associated vasculitis: Mechanisms and implications for management.

Authors:  Shangqing Ge; Xingyu Zhu; Qinyao Xu; Junyan Wang; Cheng An; Ying Hu; Fan Yang; Xinyi Wang; Yipin Yang; Shuwen Chen; Ruimin Jin; Haiyan Li; Xinchen Peng; Yue Liu; Junnan Xu; Minhui Zhu; Zongwen Shuai
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

7.  Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.

Authors:  Alessandra Bettiol; Maria Letizia Urban; Lorenzo Dagna; Vincent Cottin; Franco Franceschini; Stefano Del Giacco; Franco Schiavon; Thomas Neumann; Giuseppe Lopalco; Pavel Novikov; Chiara Baldini; Carlo Lombardi; Alvise Berti; Federico Alberici; Marco Folci; Simone Negrini; Renato Alberto Sinico; Luca Quartuccio; Claudio Lunardi; Paola Parronchi; Frank Moosig; Georgina Espígol-Frigolé; Jan Schroeder; Anna Luise Kernder; Sara Monti; Ettore Silvagni; Claudia Crimi; Francesco Cinetto; Paolo Fraticelli; Dario Roccatello; Angelo Vacca; Aladdin J Mohammad; Bernhard Hellmich; Maxime Samson; Elena Bargagli; Jan Willem Cohen Tervaert; Camillo Ribi; Davide Fiori; Federica Bello; Filippo Fagni; Luca Moroni; Giuseppe Alvise Ramirez; Mouhamad Nasser; Chiara Marvisi; Paola Toniati; Davide Firinu; Roberto Padoan; Allyson Egan; Benjamin Seeliger; Florenzo Iannone; Carlo Salvarani; David Jayne; Domenico Prisco; Augusto Vaglio; Giacomo Emmi
Journal:  Arthritis Rheumatol       Date:  2021-12-30       Impact factor: 15.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.